The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | Challenges and options for patients with hydroxyurea-resistant PV
Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL, discusses his recent publication reviewing the challenges and treatment options for patients with hydroxyurea-resistant polycythemia vera (PV). Dr Kuykendall highlights that, although hydroxyurea is still used in first-line PV treatment, a greater number of disease-modifying agents are becoming available which treat the disease in a distinct way, including interferon and JAK inhibitors. There is a need for clinicians to consider the unique situation of each patient in order to choose the best therapeutic option for the individual. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Celgene/BMS, Cogent, Incyte, Abbvie, Imago, Novartis, PharmaEssentia, CTI Biopharma, MorphoSys, GSK, Karyopharm
Research Funding: MorphoSys, BMS, Protagonist Therapeutics, Janssen
Advisory Board: Dark Blue Therapeutics
